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ABSTRACT 
Objective: The objective of the study was to develop a simple and rapid chromatographic method for quantification of escitalopram oxalate and 
flupentixol dihydrochloride in combined dosage form and plasma. 
Methods: The separation was achieved with a sun fire C 8 
Results: The HPLC method was developed and validated with respective linearity, accuracy, and precision, detection of limit, robustness, and 
specificity. The precision of the results stated as the relative standard deviation was below 2 %. The calibration curve was linear over a 
concentration range from 10-50 µg/ml for escitalopram oxalate and 1-5 µg/ml for flupentixol dihydrochloride with a correlation co-efficient 0.994 
and 0.977 respectively. The accuracy of the method was demonstrated at levels in the range of 100 % and 120 % of the specification limit. The 
recovery of escitalopram oxalate and flupentixol dihydrochloride was found to be in the range of 90 % to 88 %, respectively. The lowest detection 
limits were found to be 2 µg/ml for escitalopram oxalate and 0.1 µg/ml for flupentixol dihydrochloride. The lowest quantification limits were found 
to be 5 µg/ml of escitalopram oxalate and 0.5 µg/ml of flupentixol dihydrochloride. 
[150×4.6 mm] 3.5 µm column with an isocratic mobile phase containing a mixture of 
potassium dihydrogen orthophosphate buffer: methanol: acetonitrile [30:60:10 v/v/v] pH adjusted to 11. The flow rate of the mobile phase was 
1.5 ml/min with a Photodiode array [PDA] detection at 230 nm. 
Conclusion: The developed method was validated for linearity, accuracy, precision, the limit of detection and quantification, specificity. The method 
was applied successfully for the determination of escitalopram oxalate and flupentixol dihydrochloride in the combined dosage form and plasma.  
Keywords: Escitalopram oxalate, Flupentixol dihydrochloride, High-performance liquid chromatography, Human plasma, Validation 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (https://creativecommons.org/licenses/by/4.0/) 
DOI: https://dx.doi.org/10.22159/ijpps.2021v13i2.30158. Journal homepage: https://innovareacademics.in/journals/index.php/ijpps.  
 
INTRODUCTION 
Depression is a mood disorder that causes a persistent feeling of 
sadness and loss of interest, also called a major depressive disorder 
or clinical depression, it affects feel, think, and behave and can lead 
to a variety of emotional and physical problems. Escitalopram 
oxalate [ESC] is an orally administered selective serotonin reuptake 
inhibitor. It is the pure S enantiomers of racemic bicyclic phthalate 
derivative of citalopram. Chemically it is S-1-[3-Dimethylamino]-
propyl]-1-[4-flurophenyl]-1, dihydro isobenzofuran-5-carbonitrile 
[1]. ESC is used to treat depression and anxiety. It works by helping 
to restore the balance of a certain natural substance [serotonin] in 
the brain. ESC belongs to a class of drugs known as Selective 
Serotonin Reuptake Inhibitors [SSRI]. It may improve your energy 
level and feelings of well-being and decrease nervousness. 
Flupentixol dihydrochloride [FLU] is an antipsychotic narcoleptic 
drug. It is a thioxanthene and therefore closely related to the 
phenothiazines. Chemically it is [EZ]-2-[4-[3-[2-[trifluoro-methyl] 
thioxanthen-9-ylidene] Propyl] piperazin-1-yl] ethanol 
dihydrochloride [2]. Its primary use is as a long-acting injection given 
two or three weekly to people with schizophrenia who have poor 
compliance with medication and suffer frequent relapses of illness. It 
is a D1 and D2 receptor antagonist. A Literature survey revealed that 
several methods are developed for ESC and FLU individually [3-10]. 
Liquid chromatographic methods and UV first derivative methods 
have been developed for ESC and FLU in pharmaceutical dosage form 
[11-14]. To the best of our knowledge, no information related to the 
high-performance liquid chromatography determination of ESC and 
FLU in pharmaceutical dosage form and plasma has ever been 
mentioned in the literature. So the present study was aimed to develop 
a precise, rapid analytical method for estimation of ESC and FLU in 
combined dosage form and plasma. The developed method was 
validated according to the ICH guidelines [15]. 
MATERIALS AND METHODS 
Instruments  
The chromatography analysis was performed using a Shimadzu 
HPLC module Shimadzu SPD-M10 AVP, Japan equipped with a PDA 
detector, gradient solvent manager, and manual sample system. The 
pH of the solutions was measured by pH meter Lab India, India. 
Chemicals and reagent 
Shangri-La industries supplied a sample of ESC and FLU. Methanol 
HPLC grade and potassium dihydrogen orthophosphate were 
purchased in himedia laboratory pvt Ltd, Mumbai. Water for HPLC 
was purchased in thermo fisher scientific, Mumbai. Acetonitrile 
HPLC grade was purchased in sigma Aldrich chemicals pvt Ltd, 
Bangalore. Ammonia solution was purchased in Loba chem. Mumbai.  
Chromatographic conditions 
The method was developed by using sun fire C 8 
Preparation of diluents 
[150×4.6 mm] 3.5 
µm column with an isocratic mobile phase containing a mixture of 
potassium dihydrogen orthophosphate: methanol: acetonitrile 
[30:60:10 v/v/v]. The pH was adjusted to 11. The Flow rate of the 
mobile phase was 1.5 ml/min. The eluted compounds were 
monitored at a wavelength of 230 nm [11]. 
Methanol was used as diluents for this experiment. 
Preparation of the mobile phase 
A mixture of potassium dihydrogen orthophosphate, methanol and 
acetonitrile in the ratio of 30:60:10 [v/v/v] was prepared and the pH 
adjusted to 11 with 30 % ammonia solution.  
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Preparation of standard solution 
A Combined standard stock solution containing 1000 µg/ml of ESC and 
FLU was prepared in methanol. The standard working solution of ESC 
and FLU were prepared by serial dilution of the stock solution. This 
stock solution was diluted appropriately to prepare the standard of 
ESC was 10-50 µg/ml and FLU was 1-5 µg/ml, respectively [13]. 
Preparation of sample solution 
The sample solution was prepared by taking ten tablets containing 5 
mg of ESC and 0.5 mg of FLU were weighed; the average weight was 
determined and ground to a fine powder using a glass mortar and 
pestle. An equivalent of 10 mg ESC and 1 mg of FLU was accurately 
weighed and transferred to a separate 100 ml volumetric flask, The 
volume was adjusted with methanol and the resultant solution was 
sonicated for 15 min. This solution was then filtered through 
Whatmann filter paper. Further dilutions were made from this stock 
solution to get the required concentration [13].  
Validation procedure 
Method validation was achieved as per ICH guidelines for the 
determination of ESC and FLU. The following validation features 
were addressed linearity, detection limit, quantification limit, 
precision, accuracy, robustness, and specificity [15]. 
Linearity 
Standard solutions at five concentrations ranging from ESC 10-15 
µg/ml and FLU 1-5 µg/ml were prepared and analyzed to 
demonstrate the linearity. The regression curve was obtained by 
plotting peak area versus concentration. The regression equation 
was obtained by using the least-squares method. 
Limits of detection and quantification [LOD and LOQ] 
The sensitivity of the method was measured by calculating the limit 
of detection and limit of quantification. LOD and LOQ were 
determined by injecting decreasing amounts of drugs. The lowest 
concentration at which peak is determined is called LOD was found 
out to be 2 µg/ml for ESC and 0.1 µg/ml for FLU. The lowest 
concentration at which peak can be quantified is called LOQ was 
found be for 5 µg/ml ESC and 0.5 µg/ml for FLU. 
Accuracy  
The standard addition and recovery experiments were conducted to 
demonstrate the accuracy of the method. The accuracy of the 
method evaluated in triplicate at two concentration levels 100 % 
and 120 % of target test concentration and the percentages of 
recoveries were calculated. 
System suitability criteria 
The system suitability test was well defined based on the result 
found in several results chromatograms. The column efficiency was 
determined from the analyte peak; the tailing factor was below 2. All 
the system suitability criteria during the validation of the study and 
batch analysis study within the acceptance limit. The results of 
system suitability depicted in table 1. 
 
Table 1: System suitability data 
Peak ESC FLU  
Retention time 2.1 min 4.8 min 
Peak area 151325 28400 
USP plate count 4123.1 3998.4 
USP tailing 1.3 1.6  
 
Preparation of standard solution 
The developed method was utilized for the estimation of ESC and 
FLU in plasma. A stock solution was prepared by dissolving 
accurately weighed 10 mg of ESC and 1 mg of FLU in 10 ml of 
methanol to yield a concentration of 1000 µg/ml of ESC and 100 
µg/ml of FLU, respectively. The solution was sonicated for 20 min 
serious of aliquots of drug solution containing 10-50 µg/ml of ESC 
and 1-5 µg/ml of FLU were prepared. To each of the five centrifuge 
tubes, 0.5 ml of the above-prepared solutions were transferred. To 
this 0.5 ml of plasma was added and 1 ml of extracting solvent of 
methanol was added to the tube and centrifuged for 20 min at 3000 
Revolution per minute [RPM]. Further supernatant liquids were 
collected in another eppendorf tube and the supernatant was 
injected into the analytical column. 
Preparation of sample solution 
A Fixed-dose working sample was prepared according to the dosage 
form of rexipra fx 5tablets. Accurately weighed samples of rexipra fx 5 
contains 5: 0.5 mg of ESC and FLU were transferred into a 10 ml 
volumetric flask, dissolved in methanol and sonicated for 20 min and 
filtered the solution and from that aliquots solution are prepared. 
From the above-prepared sample solution [ESC 10-50 µg/ml and FLU 
1-5 µg/ml], 0.5 ml was pipette out and spiked into 0.5 ml of plasma in 
a polypropylene tube [Torson’s] then the tube was cyclomixed for 5 
min. Then the 1 ml of methanol was added to the tube and centrifuged 
for 20 min at 3000 rpm. Further supernatant liquids were collected in 
another eppendorf tube and the supernatant was injected into the 
analytical column. The calibration curve was plotted using the peak 
area of standard drugs Vs concentration of the standard solution. The 
peak area of the sample chromatogram was compared and the amount 
of ESC and FLU was calculated. 
Extracting procedure 
ESC 10-50 µg/ml and 1-5 µg/ml of FLU, 0.5 ml was pipette out and 
spiked into 0.5 ml of plasma in a polypropylene tube [Torson’s]. 
Then the tube was cyclomixed for 5 min. Then the 1 ml of methanol 
was added to the tube and centrifuged for 20 min at 3000 RPM. 
Further supernatant liquids were collected in another eppendorf 
tube and the supernatant was injected into the analytical column. 
Chromatographic conditions 
The drug was estimated at 230 nm using a photodiode array 
detector to maximize the signal of the compound and minimize the 
signal of plasma interferents. The chromatographic separation was 
performed on a C8
Validation 
 column [150 mm length × 4.6 mm diameter, 5 µm 
particle size] Sunfire column. The mobile phase consists of 
potassium dihydrogen orthophosphate: methanol: acetonitrile 
[30:60:10] pH adjusted to 11. The mobile phase is pumped at a flow 
rate of 1.5 ml/min. The mobile phase was sonicated for 15 min using 
an ultrasonicator. The developed HPLC method was optimized by 
monitoring chromatographic parameters, including retention time, 
column efficiency of the several compositions, and flow rate of the 
mobile phase. 
The suggested analytical method was validated according to ICH 
guidelines for certain parameters such as selectivity, linearity, 
accuracy, LOD, LOQ and precision. Methanol was used as an 
extraction solvent as the efficiency of the extraction was more with 
methanol than with other solvents. 
Linearity 
To find out the linearity range of the proposed HPLC method in 
plasma, curves were constructed by plotting peak areas obtained for 
the analyte against their concentrations. A good linear relationship 
[R2 =0.99] was observed between the concentration of ESC and FLU 
and their corresponding peak areas. The relevant regression 
equations were Y=9588x+44345 and Y= 15659X+14881[where Y is 
the peak area and X is the concentration of ESC and FLU [µg/ml]. The 
slope, intercept, and correlation coefficient of the plots for ESC was 
Sellappan et al. 
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9588, 44345 and 0.995. The slope, intercept, and correlation 
coefficient of the plots for the FLU was 15659, 14881 and 0.970. The 
linearity range for ESC and FLU and their corresponding graphs are 
shown in fig.1 and 2. 
 
 
Fig. 1: Linearity graph of ESC 
 
 
Fig. 2: Linearity graph of FLU 
 
Precision 
The Precision of the method was ascertained in terms of 
repeatability, intraday and interday precision. Repeatability was 
determined by injecting 30 µg/ml of ESC and 3 µg/ml of FLU in six 
replicates and respective areas were calculated. For intra-day and 
inter-day variations, three concentrations of 20, 30 and 40 µg/ml for 
ESC and 2, 3 and 4 µg/ml for FLU were selected from the linearity 
range. Intraday analysis was carried on the same day in three 
replicates. The interday analysis was carried on three different days 
in three replicates. The precision of the proposed method i.e., the 
intra and inter-day variations in the peak areas of the drugs 
solutions in plasma was calculated in terms of % Relative standard 
deviation [RSD] and the results are represented in tables 3,4 and 5. 
Statistical evaluation revealed that the % RSD of the drugs at 
linearity levels for 6 injections was less than 2.0. 
Limit of detection and quantification [LOD and LOQ] 
LOD for ESC and FLU in plasma were found to be 2 µg/ml and 
0.1µg/ml, respectively. The LOQ for ESC and FLU in plasma was 
found to be 5 µg/ml and 0.5 µg/ml, respectively. 
Peak purity 
A Peak purity test was performed for the standard drug peaks. Peak 
purity index values of ESC and FLU were found to be 0.999, 
respectively. Values close to one indicates the purity of the peaks. 
RESULTS AND DISCUSSION 
Chromatogram depicting the method development of ESC and 
FLU 
A novel, precise and bioanalytical method was developed for the 
simultaneous estimation of ESC and FLU in plasma samples using 
sun fire C8 [150×4.6 mm] 3.5 µm column with a mobile phase 
containing a mixture of potassium dihydrogen orthophosphate 
buffer: methanol: acetonitrile [30:60:10 v/v/v] pH adjusted to 11. 
The flow rate of the mobile phase was 1.5 ml/min with [PDA] 
detection at 230 nm. The chromatogram [fig. 3] obtain from 
method 1 was found to be no FLU peak; only ESC gave a single 
sharp peak. The chromatogram [fig. 4] attain for method 2 was 
found to be no ESC and FLU peak. The chromatogram [fig. 5] 
accessed for method 3 was found to be no ESC peak; only FLU gave 
a peak. From the above methods, ESC gave a peak with methanol 
and FLU gave a peak with acetonitrile. Accordingly, further trials 
were performed by altering the mobile phase system. The 
chromatogram [fig. 6] gathered for method 4 were found to be 
good peak shape, but it was not properly separated. Finally, the 
chromatogram [fig. 7] the method 5 was found to be perfect to 
eluted peak with excellent peak shape the tailing factor and 
retention time were observe within the limit; therefore, the mobile 
phase ratio was fixed at methanol: acetonitrile: buffer [60:10:30] 
pH 11 with 1.5 ml/min flow rate. The retention time for ESC and 
FLU was 2.1 and 4.8, respectively. 
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Fig. 3: HPLC chromatogram for method 1 
 
 
Fig. 4: HPLC chromatogram for method 2 
 
 
Fig. 5: HPLC chromatogram for method 3 
 
 
Fig. 6: HPLC chromatogram for method 4 
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Fig. 7: HPLC chromatogram for method 5 
 
A Literature survey revealed that several methods were developed 
for ESC and FLU individually [3-10]. UV first derivative method has 
been developed for ESC and FLU in pharmaceutical dosage form 
[14]. There are some HPLC methods [11-13] reported in the 
literature, but these methods are developed only for routine analysis 
of ESC and FLU in bulk and formulation studies, not for plasma. No 
information related to the high-performance liquid chromatography 
determination of ESC and FLU in plasma has ever been mentioned in 
the literature. The developed HPLC method was utilized for the 
estimation of the combined drugs by in vitro method. Different 
extractions were tried using acetonitrile, methanol, and 
dimethylformamide. Extraction efficiency was good in methanol. So 
methanol was selected as the solvent. Retention time of ESC and FLU 
were found to be 2.0 min and 4.3 min, respectively. The method 
highlights the importance of the liquid phase extracting technique in 
bio-analytical sample preparation. Calibration curve was plotted 
using peak area of standard drugs Vs concentration of the standard 
solution. The relevant regression equations were 0.994 for ESC and 
0.977 for FLU. The inter-day and intra-day variations in plasma by 
the proposed method showed percentage relative standard 
deviation were less than 2 %, indicating that the method is precise. 
Accuracy  
Accuracy of the method was determined by replicates [n= 2] analysis, 
carried out using three solutions prepared by standard addition of pure 
active pharmaceutical ingredients at two different concentration levels 
100 % and 120 %. Accuracy was calculated by comparing the difference 
between the spiked value [theoretical value] and that actually found 
value. Results are presented in the term of % recovery of the active 
pharmaceutical ingredients. The results are shown in table 2. 
 
Table 2: Accuracy 
S. No. Level % Recovery % RSD* 
ESC FLU ESC FLU  
 1. 100 % 90.2 89.7 0.82 0.71  
 2. 120 % 88.3 85.3 0.63 0.94 
*Relative standard deviations  
 
Table 3: Interday precision 
S. No. Drug name Concentration [µg/ml]  [ mean ± SD] % RSD* 
1. ESC 20 391260.7± 5894.9 1.5 
 2. FLU 2 245287.7± 2066.3 0.84 
*Relative standard deviations [n=3] SD = Standard deviation, n= number of injection 
 
Table 4: Intraday precision 
S. No. Drug name Concentration [µg/ml]  [mean ± SD] % RSD* 
1. ESC 20 286000±5993.8 2.09 
2. FLU 2 214557.7±3358.1 1.56 
*Relative standard deviations [n=3] SD = Standard deviation, n= number of injection 
 
Table 5: Repeatability 
S. No. Drug name Concentration [µg/ml]  [mean ± SD] % RSD* 
1. ESC 30 402716.7±7198.3 1.78 
2. FLU 3 298276.3 ±4579.2 1.53 
*Relative standard deviations [n=3] SD = Standard deviation, n= number of injection 
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Int J Pharm Pharm Sci, Vol 13, Issue 2, 61-66 
 
66 
Significant percentage of recovery was observed, which shows the 
extraction efficiency of the method. The chromatogram for 
combination drugs in plasma was shown in [fig. 8]. Extraction 
efficiency was determined by significant recovery studies. 
 
 
Fig. 8: Chromatogram for ESC and FLU 
 
CONCLUSION 
This article explains a simple, rapid and cost-effective method for the 
simultaneous quantification of ESC and FLU concentrations in plasma 
using HPLC coupled with PDA detector. Additionally, the method 
involves a simple and novel liquid phase extraction technique to 
process the bio-analytical samples. The ease of the method makes it 
more appropriate for regular therapeutic drug monitoring.  
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